Last reviewed · How we verify

Ewing's sarcoma — Treatment Landscape & Competitive Intelligence

Ewing's sarcoma (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Ewing's sarcoma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Temodar temozolomide Merck & Co. Alkylating Drug [EPC] 1999-01-01
Cosmegen DACTINOMYCIN Recordati Actinomycin [EPC] DNA 1964-01-01
Temodal Temodal Armando Santoro, MD

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Armando Santoro, MD · 1 drug in Ewing's sarcoma
  2. Merck & Co. · 1 drug in Ewing's sarcoma
  3. Recordati · 1 drug in Ewing's sarcoma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Ewing's sarcoma:

Cite this brief

Drug Landscape (2026). Ewing's sarcoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/ewing-s-sarcoma. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing